anti-CD19-CAR CMV-specific T-lymphocytes

Anti-CD19-CAR CMV-specific T-lymphocytes are a form of adoptive cell therapy in which human cytomegalovirus (CMV) pp65 antigen–specific T lymphocytes are genetically modified ex vivo to express a chimeric antigen receptor (CAR) targeting the B-cell surface protein CD19. This engineering creates bispecific effector cells that can recognize and kill both CD19-expressing tumor cells and respond to stimulation by the native CMV antigen via their endogenous T-cell receptor. Upon administration, these engineered lymphocytes bind to and induce selective toxicity in malignant B-cells expressing CD19, while also being capable of expansion in vivo upon exposure to a CMV vaccine or natural infection. This dual specificity is designed to enhance persistence and antitumor activity of the infused CAR-T product by leveraging both CAR-mediated tumor targeting and physiological expansion through viral antigen stimulation. The approach is under clinical investigation primarily for hematologic malignancies such as B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma[3][5][7].

Other names

CMV-CD19CAR T cellsCMV-CD-19CAR T cellsCMV-CD 19CAR T cellsCMV-specific CD19 CAR T cellsbi-specific CAR T cells (CMV/CD19)anti-CD19 chimeric antigen receptor cytomegalovirus-specific T lymphocytesanti-CD-19 chimeric antigen receptor cytomegalovirus-specific T lymphocytesanti-CD 19 chimeric antigen receptor cytomegalovirus-specific T lymphocytes